Success Metrics

Clinical Success Rate
85.6%

Based on 101 completed trials

Completion Rate
86%(101/118)
Active Trials
4(3%)
Results Posted
59%(60 trials)
Terminated
17(13%)

Phase Distribution

Ph not_applicable
1
1%
Ph phase_2
71
53%
Ph phase_3
11
8%
Ph early_phase_1
1
1%
Ph phase_1
50
37%

Phase Distribution

51

Early Stage

71

Mid Stage

11

Late Stage

Phase Distribution134 total trials
Early Phase 1First-in-human
1(0.7%)
Phase 1Safety & dosage
50(37.3%)
Phase 2Efficacy & side effects
71(53.0%)
Phase 3Large-scale testing
11(8.2%)
N/ANon-phased studies
1(0.7%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

84.2%

101 of 120 finished

Non-Completion Rate

15.8%

19 ended early

Currently Active

4

trials recruiting

Total Trials

135

all time

Status Distribution
Active(4)
Completed(101)
Terminated(19)
Other(11)

Detailed Status

Completed101
Terminated17
unknown11
Active, not recruiting4
Withdrawn2

Development Timeline

Analytics

Development Status

Total Trials
135
Active
4
Success Rate
85.6%
Most Advanced
Phase 3

Trials by Phase

Early Phase 11 (0.7%)
Phase 150 (37.3%)
Phase 271 (53.0%)
Phase 311 (8.2%)
N/A1 (0.7%)

Trials by Status

active_not_recruiting43%
terminated1713%
completed10175%
unknown118%
withdrawn21%

Recent Activity

4 active trials
Showing 5 of 135
active_not_recruitingphase_2

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

NCT00265798
active_not_recruitingphase_1

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

NCT01303341
active_not_recruitingphase_1

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

NCT01861314
completedphase_2

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

NCT00939627
completedphase_1

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

NCT03211416
View all 135 trials

Clinical Trials (135)

Showing 20 of 135 trialsScroll for more
NCT00265798Phase 2

Sorafenib in Treating Patients With Malignant Gastrointestinal Stromal Tumor That Progressed During or After Previous Treatment With Imatinib Mesylate and Sunitinib Malate

Active Not Recruiting
NCT01303341Phase 1

Riluzole and Sorafenib Tosylate in Treating Patients With Advanced Solid Tumors or Melanoma

Active Not Recruiting
NCT01861314Phase 1

Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

Active Not Recruiting
NCT00939627Phase 2

Phase II Randomized Trial of the Combination of Cetuximab and Sorafenib or Single Agent Cetuximab

Completed
NCT03211416Phase 1

Sorafenib Tosylate and Pembrolizumab in Treating Patients With Advanced or Metastatic Liver Cancer

Completed
NCT00826540Phase 2

Sorafenib and Bevacizumab in Treating Patients With Metastatic Colorectal Cancer

Completed
NCT01371981Phase 3

Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Active Not Recruiting
NCT02143401Phase 1

Navitoclax and Sorafenib Tosylate in Treating Patients With Relapsed or Refractory Solid Tumors

Completed
NCT01817751Phase 2

Sorafenib, Valproic Acid, and Sildenafil in Treating Patients With Recurrent High-Grade Glioma

Completed
NCT01578109Phase 1

Sorafenib Tosylate Before and After Donor Bone Marrow Transplant in Treating Patients With Acute Myeloid Leukemia

Completed
NCT02135874Phase 2

Clofarabine, Idarubicin, Cytarabine, Vincristine Sulfate, and Dexamethasone in Treating Patients With Newly Diagnosed or Relapsed Mixed Phenotype Acute Leukemia

Completed
NCT00096434Phase 2

Sorafenib in Treating Patients With Metastatic Breast Cancer

Completed
NCT00390325Phase 2

Sorafenib Tosylate in Treating Patients With Metastatic, Locally Advanced, or Recurrent Medullary Thyroid Cancer

Completed
NCT01004978Phase 3

Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery

Completed
NCT01624285Phase 2

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Completed
NCT00093457Phase 2

Sorafenib in Treating Patients With Metastatic or Recurrent Prostate Cancer

Completed
NCT02066181Phase 3

Sorafenib Tosylate in Treating Patients With Desmoid Tumors or Aggressive Fibromatosis

Completed
NCT00981162Phase 1

Sorafenib Tosylate and Everolimus in Treating Patients With Advanced Solid Tumors and Metastatic Pancreatic Cancer That Does Not Respond to Gemcitabine Hydrochloride

Completed
NCT01253070Phase 2

Sorafenib Tosylate and Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia

Completed
NCT01015833Phase 3

Sorafenib Tosylate With or Without Doxorubicin Hydrochloride in Treating Patients With Locally Advanced or Metastatic Liver Cancer

Completed

Drug Details

Intervention Type
DRUG
Total Trials
135